CN111588833A - Product for regulating hypertension - Google Patents

Product for regulating hypertension Download PDF

Info

Publication number
CN111588833A
CN111588833A CN202010655961.1A CN202010655961A CN111588833A CN 111588833 A CN111588833 A CN 111588833A CN 202010655961 A CN202010655961 A CN 202010655961A CN 111588833 A CN111588833 A CN 111588833A
Authority
CN
China
Prior art keywords
extract
product
packaging
materials
hypertension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010655961.1A
Other languages
Chinese (zh)
Inventor
周朝辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Dayuan Cangbaotang Health Management Co ltd
Original Assignee
Beijing Dayuan Cangbaotang Health Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Dayuan Cangbaotang Health Management Co ltd filed Critical Beijing Dayuan Cangbaotang Health Management Co ltd
Priority to CN202010655961.1A priority Critical patent/CN111588833A/en
Publication of CN111588833A publication Critical patent/CN111588833A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A61K36/355—Lonicera (honeysuckle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/066—Clavicipitaceae
    • A61K36/068—Cordyceps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/744—Gardenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969—Polygonatum (Solomon's seal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention discloses a product for regulating hypertension, which is prepared from the following raw materials: 5-6% of honeysuckle extract, 3-4% of ginseng extract, 3-4% of oyster peptide, 7-8% of kudzu root extract, 7-8% of medlar extract, 1-2% of cordyceps militaris extract, 14-21% of hawthorn extract, 3-5% of corn stigma extract, 1-3% of white gourd extract, 1-4% of gardenia extract, 4-5% of mint extract, 2-5% of rhizoma polygonati, 3-5% of sea buckthorn, 17-18% of maltodextrin, 1% of corn starch and 1% of magnesium stearate. The product for regulating the hypertension, which is prepared by matching various components in a proper proportion, has good effects of reducing the blood pressure and the blood fat, can quickly pass through the stomach to reach the small intestine, is quickly and completely absorbed, can quickly supplement the nutrition required by a hypertension patient, has no side effect after being eaten for a long time, is convenient and quick, and enhances the immunity of the organism.

Description

Product for regulating hypertension
Technical Field
The invention relates to the technical field of hypertension regulation, in particular to a product for regulating hypertension.
Background
Hypertension is a disease of persistent hypertension, which causes diseases such as stroke, heart disease, hemangioma, renal failure, etc., and is a systemic disease characterized by an increase in arterial pressure and accompanied by functional or organic changes in organs such as heart, blood vessels, brain and kidney, and is classified into primary hypertension and secondary hypertension. The causes of hypertension are many, and can be divided into genetic and environmental aspects. Under the condition of not using antihypertensive drugs, the systolic pressure is more than or equal to 140mmHg and/or the diastolic pressure is more than or equal to 90mmHg, and the hypertension is divided into 1, 2 and 3 grades according to the blood pressure level. The simple systolic hypertension is obtained by the list that the systolic pressure is more than or equal to 140mmHg and the diastolic pressure is less than 90 mmHg. The patient has a history of hypertension, and is currently taking antihypertensive drugs, and the blood pressure is lower than 140/90mmHg, and the patient should be diagnosed with hypertension.
The components in the plant protein dietary fiber powder or tablet on the market at present are only common protein and dietary fiber, have no functional food fiber, have no scientific proportion and are simply mixed, so that the protein and dietary fiber products on the market have no effect of promoting the growth of intestinal probiotics; no effect of reducing blood pressure; the effect of improving constipation is not achieved; no weight loss effect; there is no blood pressure lowering effect, and for this reason we propose a product for regulating hypertension.
Disclosure of Invention
The invention aims to solve the defects in the prior art, and provides a product for regulating hypertension.
In order to achieve the purpose, the invention provides the following technical scheme: a product for regulating hypertension is prepared from the following raw materials: 5-6% of honeysuckle extract, 3-4% of ginseng extract, 3-4% of oyster peptide, 7-8% of kudzu root extract, 7-8% of medlar extract, 1-2% of cordyceps militaris extract, 14-21% of hawthorn extract, 3-5% of corn stigma extract, 1-3% of white gourd extract, 1-4% of gardenia extract, 4-5% of mint extract, 2-5% of rhizoma polygonati, 3-5% of sea buckthorn, 17-18% of maltodextrin, 1% of corn starch and 1% of magnesium stearate;
preferably, the preparation method of the product for regulating hypertension comprises the following steps:
s1, matching 5-6% of honeysuckle extract, 3-4% of ginseng extract, 3-4% of oyster peptide, 7-8% of kudzu root extract, 7-8% of medlar extract, 1-2% of cordyceps militaris extract, 14-21% of hawthorn extract, 3-5% of corn stigma extract, 1-3% of wax gourd extract, 1-4% of gardenia extract, 4-5% of mint extract, 2-5% of rhizoma polygonati, 3-5% of sea buckthorn, 17-18% of maltodextrin, 1% of corn starch and 1% of magnesium stearate in a technical formula, sieving the matched raw materials in a batching workshop by using a 80-mesh sieve, and weighing all the sieved materials in a weighing workshop by using an electronic scale for later use;
s2, transferring the materials weighed by the weighing workshop to a trough type mixing workshop through a transfer window, putting the materials into a mixer, setting the mixing time for 15 minutes according to the process requirements, uniformly stirring the materials by using 30% alcohol as a bonding agent, then putting the materials into a granulator for granulation, putting the manufactured granules into an oven for drying, setting the drying temperature to be 70 ℃, and setting the drying time to be 2-3 hours;
s3, granulating the dried materials, and then conveying the granules to a tabletting workshop for tabletting, wherein the speed of the tabletting machine is set to be 20 r/min, the net content of each tablet is 0.6 g, the net content is checked once every 10 min, and the net content of 10 tablets is required to be 5.65-6.35 g;
s4, transferring the pressed products to an aluminum-plastic packaging workshop for packaging, packaging 12 pieces in each plate, transferring the split aluminum shrink plates to an outer packaging workshop for packaging small boxes and large boxes, shrinking each small box by using a BMD-450C full-automatic circulating shrink packaging machine for shrinking films, and packaging the shrunk products;
and S5, warehousing the product qualified in the laboratory.
Preferably, the mixer used in the step S2 is a CH-150 tank mixer.
Preferably, the granulator used in step S2 is a B-160 rocking granulator.
Preferably, the model of the tablet press in the step S3 is d80F-10100 Rl.
The pharmacology of each component in the raw materials of the invention is as follows:
honeysuckle flower:
(1) the antibacterial and antiviral effects of the antibacterial and antiviral agent are that staphylococcus aureus, hemolytic streptococcus, dysentery, typhoid fever, meningococcus, pneumococcus, pyocyanea, influenza virus and the like are obviously inhibited;
(2) the honeysuckle has the function of enhancing immunity, can promote lymphocyte transformation and enhance the phagocytic function of white blood cells;
(3) has antiinflammatory and antipyretic effects, and flos Lonicerae has effect in promoting release of adrenocortical hormone and inhibiting inflammation.
Ginseng: has effects of invigorating primordial qi, invigorating spleen, benefiting lung, promoting fluid production, tranquilizing mind, and improving intelligence. In modern pharmaceutical research, ginseng has the effects of resisting shock, strengthening heart, resisting fatigue, regulating cholesterol, regulating immunity of an organism, reducing blood sugar, resisting inflammation, resisting allergy, resisting diuresis and resisting tumors.
Oyster peptide:
(1) the composition has obvious platelet aggregation inhibiting effect, can reduce the blood fat of patients with hyperlipidemia and the content of TXA2 in blood, is beneficial to the secretion and utilization of insulin, can enhance the sensitivity of malignant tumor cells to radioactive rays, and has inhibiting effect on the growth of malignant tumor cells;
(2) the taurine contained in the oyster has obvious functions of protecting liver and benefiting gallbladder, which is also a good medicine for preventing and treating liver and gallbladder juice stasis during pregnancy;
(3) rich trace elements and glycogen are contained, and the health care product is beneficial to promoting the growth and development of fetuses, correcting anemia of pregnant women and restoring physical strength of the pregnant women;
(4) oyster is the best food for supplementing calcium, contains rich phosphorus, and is beneficial to calcium absorption because the calcium is absorbed by the body with the help of the phosphorus;
(5) the oyster also contains vitamin B12 which is absent in common food, and vitamin B12 contains diamond element which is indispensable in preventing pernicious anemia, so the oyster has the function of activating hematopoiesis;
(6) the protein contained in Concha Ostreae contains various excellent amino acids, which have detoxifying effect and can remove toxic substances in vivo, and the taurine has blood cholesterol concentration lowering effect, so that arteriosclerosis can be prevented;
(7) every hundred grams of oyster, zinc element is as high as 13.2 milligrams, male can meet the body to the demand of zinc to eat one every day.
Kudzu root:
(1) improving regeneration capacity of liver cell, recovering normal liver function, promoting bile secretion, and preventing fat accumulation in liver;
(2) promoting metabolism, enhancing liver detoxification function, and preventing alcohol damage to liver;
(3) for coronary arteriosclerosis caused by hyperlipemia, cardiovascular diseases such as coronary heart disease, angina pectoris, myocardial infarction, etc. can be prevented and treated by improving myocardial ischemia state;
(4) for cerebral arteriosclerosis caused by hyperlipemia, cerebral ischemia state can be improved, and cerebrovascular diseases such as cerebral infarction, hemiplegia, vascular dementia, etc. can be prevented and treated;
(5) enhance the autoimmune function of liver and gall cells and resist virus invasion.
Medlar: the health-care tea can nourish liver and kidney, replenish vital essence to improve eyesight, nourish blood and enhance immunity of people; fatigue resistance and blood pressure reduction; the medlar can protect the liver, reduce the blood sugar, soften the blood vessel, reduce the cholesterol and triglyceride level in the blood, and has certain curative effect on fatty liver and diabetes patients; according to clinical medical verification, the medlar can also treat chronic renal failure.
Cordyceps militaris: invigorating kidney, benefiting lung, enhancing immunity, resisting tumor, and resisting bacteria.
Hawthorn fruit:
(1) preventing and treating cardiovascular diseases, lowering blood pressure and cholesterol, softening blood vessel, promoting urination and tranquilizing;
(2) the hawthorn is adopted in a plurality of medicines for helping digestion;
(3) the hawthorn has the efficacy of activating blood and dissolving stasis, is beneficial to relieving the local blood stasis state, and has auxiliary curative effect on traumatic injury;
(4) the hawthorn contains the components for relieving asthma, reducing phlegm, inhibiting bacteria and treating abdominal pain and diarrhea.
Corn silk: contains abundant proteins and vitamins, and can keep the functions of heart, blood, skeleton, muscle and nerve of human body normal;
white gourd: clearing away heat and toxic materials, promoting urination, quenching thirst, relieving restlessness, eliminating dampness, relieving summer-heat, and removing fish toxin. The main treatment is as follows: abscess and swelling due to heat toxin, dysuria, feverish sensation in the chest, thirst, fever and distending sensation in the lower abdomen.
Gardenia: clearing heat, purging fire, cooling blood; it is used to treat febrile diseases, vexation, insomnia, jaundice, gonorrhea, diabetes, conjunctival congestion, pharyngalgia, hematemesis, epistaxis, dysentery with blood, hematuria, pyocutaneous disease due to heat toxin, sprain, and swelling and pain.
Mint:
(1) dispelling wind-heat, clearing head and eyes, relieving sore throat, promoting eruption, dispersing stagnated liver qi, relieving qi stagnation, and removing toxic substance, and herba Menthae is often used for treating headache due to wind-heat, conjunctival congestion, sore throat, food stagnation, flatulence, aphtha, toothache, skin ulcer, furuncle, and red swelling. The mint has the main effects of refreshing and eliminating fatigue, and is beneficial to relieving depression due to the faint scent of the mint, the mint can stimulate nerves and has positive effects on the psychology and physiology of people;
(2) the mint has the effect of clearing away summer-heat, and because the main component of the mint is mint oil, the mint oil can promote the expansion of capillary vessels and the increase of sweat gland secretion, and has the effect of relieving fever and relieving summer-heat through sweating;
(3) the mint has the functions of appetizing and deodorizing, and because the mint has faint scent, can prevent corrosion and deodorize, has fragrance and avoids dirtiness, the menthol and the menthone contained in the mint can dissipate heat and detoxify and promote appetite;
(4) has analgesic and antipruritic effects, and the topical application of herba Menthae containing menthol can be used for treating headache and neuralgia;
rhizoma polygonati: rhizoma Polygonati can be used for treating weakness of spleen and stomach, yin deficiency, lung dryness, dry cough, little phlegm, premature gray hair, essence and blood deficiency, internal heat, diabetes, etc.; modern medical research shows that rhizoma polygonati also has the effects of reducing blood pressure, blood sugar and blood fat, preventing atherosclerosis, delaying senility and resisting bacteria, has a good curative effect on diabetes and has an inhibiting effect on various bacteria and dermatophytes.
Sea-buckthorn:
(1) 428 active substances contained in the sea buckthorn have the effects, wherein VC can improve immunity, resist viruses and allergy; VE has effects of resisting oxidation, scavenging free radicals, resisting cancer, and resisting aging; the flavonoid has anticancer, free radical scavenging, radioprotective, blood circulation improving, heart protecting, cholesterol and triglyceride reducing effects;
(2) the oxidation resistance and the anticancer effect of the procyanidin contained in the sea buckthorn are 20 times of that of VC and 50 times of that of VE. The mineral selenium rich in fructus Hippophae can activate immune system, protect cell membrane, prevent gene mutation, and has anticancer and antioxidant effects;
(3) the SOD rich in the sea buckthorn is an antioxidant with the highest activity found at present, has good effect on treating autoimmune diseases, and can effectively improve the serious reduction of leucocytes caused by chemotherapy and enable the leucocytes to recover to be normal;
(4) sea buckthorn contains many active anticancer components, such as 5-hydroxytryptamine, which have obvious anticancer effect, and can also regulate immunity and enhance the resistance to cancer by supplementing trace elements, vitamins and the like.
The invention has the technical effects and advantages that:
1. the product for regulating the hypertension, which is prepared by matching various components in a proper proportion, has good effects of reducing the blood pressure and the blood fat, can quickly pass through the stomach to reach the small intestine, is quickly and completely absorbed, can quickly supplement the nutrition required by a hypertension patient, has no side effect after being eaten for a long time, is convenient and quick, and enhances the immunity of the organism.
2. The product for regulating the hypertension, which is prepared by the invention, has functional dietary fiber and scientific proportion, and has the effects of promoting the growth of intestinal probiotics, promoting the repair of intestinal mucosa injury, promoting the discharge of heavy metal, treating constipation and reducing blood pressure.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
5-6% of honeysuckle extract, 3-4% of ginseng extract, 3-4% of oyster peptide, 7-8% of kudzu root extract, 7-8% of medlar extract, 1-2% of cordyceps militaris extract, 14-21% of hawthorn extract, 3-5% of corn stigma extract, 1-3% of white gourd extract, 1-4% of gardenia extract, 4-5% of mint extract, 2-5% of rhizoma polygonati, 3-5% of sea buckthorn, 17-18% of maltodextrin, 1% of corn starch and 1% of magnesium stearate;
the preparation method comprises the following steps:
s1, preparing qualified raw materials: 5-6% of honeysuckle extract, 3-4% of ginseng extract, 3-4% of oyster peptide, 7-8% of kudzu root extract, 7-8% of medlar extract, 1-2% of cordyceps militaris extract, 14-21% of hawthorn extract, 3-5% of corn stigma extract, 1-3% of white gourd extract, 1-4% of gardenia extract, 4-5% of mint extract, 2-5% of rhizoma polygonati, 3-5% of sea buckthorn, 17-18% of maltodextrin, 1% of corn starch and 1% of magnesium stearate, then sieving the proportioned raw materials in a batching plant by using an 80-mesh sieve, and weighing all the sieved materials in a weighing room by using an electronic scale for later use;
s2, transferring the weighed materials in the weighing workshop to a trough type mixing workshop through a transfer window, putting the materials into a CH-150 trough type mixing machine, setting the mixing time for 15 minutes according to the process requirements, using 30% alcohol as an adhesive to stir uniformly, using a YB-160 swing granulator to granulate, putting the manufactured granules into an oven to dry, setting the drying temperature at 70 ℃, and setting the drying time at 2-3 hours;
s3, granulating the dried materials, and then conveying the granules to a tabletting workshop for tabletting, wherein the tablet machine adopts a model d80F-10100Rl, the speed of the tablet machine is set to be 20 r/min, the net content of each tablet is 0.6 g, the net content is checked once every 10 min, and the net content of 10 tablets is required to be 5.65-6.35 g;
s4, transferring the pressed products to an aluminum-plastic packaging workshop for packaging, packaging 12 pieces in each plate, transferring the split aluminum shrink plates to an outer packaging workshop for packaging small boxes and large boxes, shrinking each small box by using a BMD-450C full-automatic circulating shrink packaging machine for shrinking films, and packaging the shrunk products;
and S5, warehousing the product qualified in the laboratory.
Example 2
Grouping and dosing animals, namely, 8 WKY rats are normal control groups (normal groups for short), 40 SHRs are bred in a constant-temperature observation room at the room temperature of 21 +/-2 ℃, the room temperature is 12h/d under artificial illumination, and water is freely drunk; after 2 weeks, measuring blood pressure, wherein the rats with essential hypertension (SHR) higher than 22.7kPa are randomly divided into 5 groups, namely a model group (drinking water), a high-dose group, a medium-dose group and a low-dose group (20 mg crude drug/KG, 10mg crude drug/mL and 5mg crude drug/mL) of the traditional Chinese medicine compound antihypertensive capsules, a control group (captopril 0.35mg/KG per time), 8 rats in each group are respectively subjected to gastric gavage every day, the body mass is weighed 1 time per week, the dosage is adjusted according to the body mass, each group is fed with common feed and freely drinks water during the experiment, the administration time is 4 weeks, and the changes of systolic pressure (SAP) and Diastolic Pressure (DPA) of the rats are detected every 3 days; the dosage is as follows: general treatment groups: captopril 100mg/kg is administrated 2 times a day;
as a result:
TABLE 1 Effect of SAP on different time periods in groups of rats
Before administration (mmHg) One week of administration (mmHg) Two weeks of administration (mmHg) Three weeks (mmHg) Administration four weeks (mmHg)
Normal group 99.8±7.4* 98.2±11.4* 100.±9.4* 102±8.4* 104±7.4*
Model set 168.8±10.4* 171.8±10.4* 178±8.4* 179.8±10.4* 179.9±11.4*
Control group 168.8±9.4* 151.8±13.4* 143.8±9.7* 142.8±8.4* 139.8±7.6*
Low dose group 169±14.41* 170±12.51* 168±11.51* 164±10.51* 161.1±10.1*
Middle dose group 170.2±15* 168±11.32* 164±11.32* 156.7±7.32* 153.2±9.32*
High dose group 170.25±17* 156.2±18* 153.2±17* 154.4±17.3* 148.2±15.1*
All values are expressed as mean ± sd,. p < 0.05;
TABLE 2 Effect of DPA on different time periods in groups of rats
Before administration (mmHg) One week of administration (mmHg) Two weeks of administration (mmHg) Three weeks (mmHg) Administration four weeks (mmHg)
Normal group 71.8±7.22* 74.2±8.42* 72.8±9.4* 72.98±7.42* 74.39±7.32*
Model set 117.8±10.4* 122.6±9.4* 125±11.35* 123.8±10.4* 129.6±10.3*
Control group 118.8±10.4 102.8±9.42* 100.3±9.7 98.81±8.42 95.62±7.68
Low dose group 119.2±9.41 116±11.51 112±10.51 102.3±9.51* 100.72±9.1*
Middle dose group 116.5±10.2 116.7±9.02 103±10.32* 98.7±9.32* 98.32±8.32
High dose group 118.5±10.3 103.12±10* 100.2±17* 97.54±8.37 98.32±7.91
All values are expressed as mean ± sd,. p < 0.05;
before treatment, the blood pressure of rats in each group has no obvious difference, and after treatment for 4 weeks, the common treatment group and the treatment group of the invention can obviously reduce the systolic pressure and diastolic pressure of the rats with metabolic hypertension; the results suggest that the capacity of the preparation of the invention is sufficient for hypertension of rats.
Finally, it should be noted that: although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that modifications may be made to the embodiments or portions thereof without departing from the spirit and scope of the invention.

Claims (5)

1. A product for regulating hypertension, which is characterized in that: is prepared from the following raw materials:
5-6% of honeysuckle extract, 3-4% of ginseng extract, 3-4% of oyster peptide, 7-8% of kudzu root extract, 7-8% of medlar extract, 1-2% of cordyceps militaris extract, 14-21% of hawthorn extract, 3-5% of corn stigma extract, 1-3% of white gourd extract, 1-4% of gardenia extract, 4-5% of mint extract, 2-5% of rhizoma polygonati, 3-5% of sea buckthorn, 17-18% of maltodextrin, 1% of corn starch and 1% of magnesium stearate.
2. A product for regulating hypertension according to patent claim 1, characterized in that: the preparation method of the product for regulating hypertension comprises the following steps:
s1, matching qualified raw materials according to a process formula of 5-6% of honeysuckle extract, 3-4% of ginseng extract, 3-4% of oyster peptide, 7-8% of kudzu root extract, 7-8% of medlar extract, 1-2% of cordyceps militaris extract, 14-21% of hawthorn extract, 3-5% of corn stigma extract, 1-3% of wax gourd extract, 1-4% of gardenia extract, 4-5% of mint extract, 2-5% of rhizoma polygonati, 3-5% of sea buckthorn, 17-18% of maltodextrin, 1% of corn starch and 1% of magnesium stearate, sieving the matched raw materials in a batching plant by using an 80-mesh sieve, and weighing all the sieved materials in a weighing plant by using an electronic scale for later use;
s2, transferring the materials weighed by the weighing workshop to a trough type mixing workshop through a transfer window, putting the materials into a mixer, setting the mixing time for 15 minutes according to the process requirements, uniformly stirring the materials by using 30% alcohol as a bonding agent, then putting the materials into a granulator for granulation, putting the manufactured granules into an oven for drying, setting the drying temperature to be 70 ℃, and setting the drying time to be 2-3 hours;
s3, granulating the dried materials, and then conveying the granules to a tabletting workshop for tabletting, wherein the speed of the tabletting machine is set to be 20 r/min, the net content of each tablet is 0.6 g, the net content is checked once every 10 min, and the net content of 10 tablets is required to be 5.65-6.35 g;
s4, transferring the pressed products to an aluminum-plastic packaging workshop for packaging, packaging 12 pieces in each plate, transferring the split aluminum shrink plates to an outer packaging workshop for packaging small boxes and large boxes, shrinking each small box by using a BMD-450C full-automatic circulating shrink packaging machine for shrinking films, and packaging the shrunk products;
and S5, warehousing the product qualified in the laboratory.
3. A product for regulating hypertension according to claim 2, characterized in that: the mixer used in the step S2 was a CH-150 tank mixer.
4. A product for regulating hypertension according to claim 2, characterized in that: the granulator used in the step S2 is a B-160 swing granulator.
5. A product for regulating hypertension according to claim 2, characterized in that: the tablet press is of the type d80F-10100 Rl.
CN202010655961.1A 2020-07-09 2020-07-09 Product for regulating hypertension Pending CN111588833A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010655961.1A CN111588833A (en) 2020-07-09 2020-07-09 Product for regulating hypertension

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010655961.1A CN111588833A (en) 2020-07-09 2020-07-09 Product for regulating hypertension

Publications (1)

Publication Number Publication Date
CN111588833A true CN111588833A (en) 2020-08-28

Family

ID=72186630

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010655961.1A Pending CN111588833A (en) 2020-07-09 2020-07-09 Product for regulating hypertension

Country Status (1)

Country Link
CN (1) CN111588833A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112274627A (en) * 2020-12-17 2021-01-29 姚忠泽 A rapidly disintegrating Chinese medicinal tablet for lowering blood pressure, and its preparation method
CN112450437A (en) * 2020-12-11 2021-03-09 安徽国膳生物科技有限公司 Medicated diet for people with hypertension
CN112617196A (en) * 2020-11-27 2021-04-09 成都藏源高能生物科技有限公司 Food, health-care product or pharmaceutical composition for resisting anoxia and fatigue and preparation method and application thereof
CN112690390A (en) * 2021-01-08 2021-04-23 江苏中堂健康管理有限公司 Ginseng cordyceps militaris solid beverage and preparation method thereof
CN114009770A (en) * 2021-12-01 2022-02-08 海南中食肽科生物科技有限公司 Blood pressure reducing composition and preparation method thereof
CN114159529A (en) * 2022-01-22 2022-03-11 张发升 Composition for preventing and treating hypertension and preparation method thereof
CN114344420A (en) * 2022-01-04 2022-04-15 国雅轩中医药生物科技(杭州)有限公司 Preparation for conditioning and improving blood pressure and blending method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016288A (en) * 1975-08-13 1977-04-05 Merck & Co., Inc. Compositions and method of treating hypertension
CN101264157A (en) * 2008-04-21 2008-09-17 北京中科仁和科技有限公司 Traditional Chinese medicine for treating high blood pressure
CN110559419A (en) * 2019-10-11 2019-12-13 张先奇 traditional Chinese medicine composition for preventing and conditioning hypertension and preparation method thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016288A (en) * 1975-08-13 1977-04-05 Merck & Co., Inc. Compositions and method of treating hypertension
CN101264157A (en) * 2008-04-21 2008-09-17 北京中科仁和科技有限公司 Traditional Chinese medicine for treating high blood pressure
CN110559419A (en) * 2019-10-11 2019-12-13 张先奇 traditional Chinese medicine composition for preventing and conditioning hypertension and preparation method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
威米医药: "https://www.douban.com/note/769104216/?_i=8521268xQnnfTr，"【康迈通金参肽压片】预防脑梗脑出血，控制血压最有效"", 《豆瓣》 *
深圳威米: "https://zhuanlan.zhihu.com/p/151991362?utm_source=wechat_session", 《知乎》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112617196A (en) * 2020-11-27 2021-04-09 成都藏源高能生物科技有限公司 Food, health-care product or pharmaceutical composition for resisting anoxia and fatigue and preparation method and application thereof
CN112450437A (en) * 2020-12-11 2021-03-09 安徽国膳生物科技有限公司 Medicated diet for people with hypertension
CN112274627A (en) * 2020-12-17 2021-01-29 姚忠泽 A rapidly disintegrating Chinese medicinal tablet for lowering blood pressure, and its preparation method
CN112690390A (en) * 2021-01-08 2021-04-23 江苏中堂健康管理有限公司 Ginseng cordyceps militaris solid beverage and preparation method thereof
CN114009770A (en) * 2021-12-01 2022-02-08 海南中食肽科生物科技有限公司 Blood pressure reducing composition and preparation method thereof
CN114344420A (en) * 2022-01-04 2022-04-15 国雅轩中医药生物科技(杭州)有限公司 Preparation for conditioning and improving blood pressure and blending method thereof
CN114159529A (en) * 2022-01-22 2022-03-11 张发升 Composition for preventing and treating hypertension and preparation method thereof

Similar Documents

Publication Publication Date Title
CN111588833A (en) Product for regulating hypertension
CN103549433B (en) A kind of Chinese medicine and health food with liver protecting effect
JP2023538664A (en) Compositions of ginsenoside Rg3 and ginsenoside Rg5 and their pharmaceutical uses, including antitumor effects
CN106261447A (en) A kind of hepatoprotective, the solid beverage alleviating discomfort after drinking and preparation method thereof
CN102813779A (en) Novel traditional Chinese medicine composition and preparation method and application thereof
CN102813693A (en) Novel composite and preparation method and application thereof
CN101829189B (en) Traditional Chinese medicine composition for treating allergic dermatitis
CN104382002A (en) Maca tablet for alleviating fatigue
CN108066384A (en) A kind of Chinese medicine preparation with strengthen immunity and preparation method thereof
CN102526639B (en) Chinese medicinal composition for treating hyperlipidemia and preparation method thereof
CN102872368B (en) Chinese medicine acupoint application preparation for purging fire for removing toxin
KR20040045146A (en) the natural medicines for the removing hangover and its healthy foods
CN1225259C (en) A Chinese patent medicines fomula for curing cerebral arteriosclersis and the preparation process thereof
CN102631492B (en) Chinese medicinal composition for improving immunity and resisting fatigue
CN106072569A (en) The special dietary seafood of patient&#39;s immunocyte balance is regulated during a kind of chemicotherapy
CN112023019A (en) Medicine containing active polysaccharide with effect of reducing uric acid and preparation method thereof
CN101015620A (en) Biological capsule for treating cardiac and cerebral vascular diseases
CN102599312A (en) Oligosaccharide Panax notoginseng sweet tea and preparation method thereof
CN107343943A (en) A kind of liver protection, strengthening the spleen and stomach, promote digestion Chinese medicinal soft capsule and its production method
CN106070789A (en) A kind of Moringa Semen sojae atricolor granule food intervening the strong body constitution of chronic disease rehabilitation
CN101816708A (en) Treat rheumatismal Chinese medicine composition and preparation method thereof
CN106665776A (en) Traditional Chinese medicine pastries for conditioning yin deficiency constitutions
CN101147787A (en) Red glossy ganoderma Chinese medicinal herb composition
CN107281356B (en) Stomach nourishing preparation and its preparation method
CN1094639A (en) With germanium and selenium spirulina is health preparation of main component and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200828